Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | EVP, Head of International | August 12, 2026 | August 14, 2026 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | See Remarks | February 13, 2020 | February 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,655 |
Ending reported balance
After 2026-08-12 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 46,625 · Balance 112,655 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. Row 2 · 2026-08-12 · Sale · Disposed 2,300 · Balance 110,355 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-12 · Sale · Disposed 1,000 · Balance 109,355 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-12 · Sale · Disposed 3,605 · Balance 105,750 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-08-12 · Sale · Disposed 14,568 · Balance 91,182 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-08-12 · Sale · Disposed 18,208 · Balance 72,974 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-08-12 · Sale · Disposed 17,319 · Balance 55,655 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 35,875 |
Reported balance
After 2026-08-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-12 · Exercise / conversion · Disposed 46,625 · Balance 35,875 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F8: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Trevi Therapeutics, Inc.
Report date February 13, 2020 · Filed February 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2030-02-12 | Direct | 70,000 |
Reported balance
After 2020-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-13 · Grant · Acquired 70,000 · Balance 70,000 F1: This option was granted on February 13, 2020. The 70,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 13, 2020. The 70,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2023 Filed Apr 18, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Disposition to issuerRestricted Stock Units · Derivative | 41,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046815 · tm2313124-1_4seq1.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · kind: The restricted stock units were rescinded and cancelled by mutual agreement of the reporting person and Issuer. The reporting person received French-qualified restricted stock units on April 14, 2023 as consideration for the recission and cancellation of the restricted stock previously received on February 1, 2023. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,177 | $27.03 | $31,814.31 |
DisclosureSEC source: 0001104659-23-022800 · tm236871-11_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,827 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 01:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022111 · tm236871-7_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,062 Underlying: Common Stock · 2,031 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 01:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022111 · tm236871-7_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-019828 · tm236605-4_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,312 Underlying: Common Stock · 3,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,548 | $27.66 | $42,817.68 |
DisclosureSEC source: 0001104659-23-019828 · tm236605-4_4seq1.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-019828 · tm236605-4_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 15, 2023 00:27 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,563 | $27.51 | $42,998.13 |
DisclosureSEC source: 0001104659-23-022069 · tm236871-4_4aseq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 41,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010489 · tm235340-3_4seq1.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 00:29 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 934 | $6.10 | $5,697.40 |
DisclosureSEC source: 0001104659-22-023949 · tm226880-2_4seq1.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:29 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023949 · tm226880-2_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,093 Underlying: Common Stock · 2,032 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:29 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,032 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-023949 · tm226880-2_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-22-020890 · tm226394-3_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2032-02-08 F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020890 · tm226394-3_4seq1.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-21-024415 · tm216849-4_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2031-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024415 · tm216849-4_4seq1.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Stock · 8,125 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:10 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $22.28 | $0.00 |
DisclosureSEC source: 0001104659-20-112638 · a4.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-04 F1 · derivative.exercise_date: The stock options were granted on October 5, 2020. 25% of the shares subject to the option will vest and become exercisable on October 5, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:22 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-20-004875 · doc4.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2020. The 70,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 21:04 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000899243-19-015601 · doc4.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2019. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on June 3, 2020 and as to the remaining 75% of the shares in equal monthly installments thereafter through June 3, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.